BAUMERT, B. G., HEGI, M. E., VAN DEN BENT, M. J., VON DEIMLING, A., GORLIA, T., HOANG-XUAN, K., BRANDES, A. A., KANTOR, G., TAPHOORN, M. J. B., HASSEL, M. B., HARTMANN, C., RYAN, G., CAPPER, D., KROS, J. M., KURSCHEID, S., WICK, W., ENTING, R., RENI, M., THIESSEN, B., DHERMAIN, F., BROMBERG, J. E., FEUVRET, L., REIJNEVELD, J. C., CHINOT, O., GIJTENBEEK, J. M. M., ROSSITER, J. P., DIF, N., BALANA, C., BRAVO-MARQUES, J., CLEMENT, P. M., MAROSI, C., TZUK-SHINA, T., NORDAL, R. A., REES, J., LACOMBE, D., MASON, W. P. & STUPP, R. 2016. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol, 17, 1521-1532.
ESTELLER, M., HAMILTON, S. R., BURGER, P. C., BAYLIN, S. B. & HERMAN, J. G. 1999. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res, 59, 793-7.
GERSON, S. L. 2004. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer, 4, 296-307.
HEGI, M. E., DISERENS, A. C., GORLIA, T., HAMOU, M. F., DE TRIBOLET, N., WELLER, M., KROS, J. M., HAINFELLNER, J. A., MASON, W., MARIANI, L., BROMBERG, J. E., HAU, P., MIRIMANOFF, R. O., CAIRNCROSS, J. G., JANZER, R. C. & STUPP, R. 2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 352, 997-1003.
HWANG, K., KIM, T. M., PARK, C. K., CHANG, J. H., JUNG, T. Y., KIM, J. H., NAM, D. H., KIM, S. H., YOO, H., HONG, Y. K., KIM, E. Y., LEE, D. E., JOO, J., KIM, Y. J., CHOE, G., CHOI, B. S., KANG, S. G., KIM, J. H. & KIM, C. Y. 2020. Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study). Cancer Res Treat, 52, 505-515.
KARACETIN, D., OKTEN, B., YALCIN, B. & INCEKARA, O. 2011. Concomitant temozolomide and radiotherapy versus radiotherapy alone for treatment of newly diagnosed glioblastoma multiforme. J buon, 16, 133-7.
MALMSTRöM, A., GRøNBERG, B. H., MAROSI, C., STUPP, R., FRAPPAZ, D., SCHULTZ, H., ABACIOGLU, U., TAVELIN, B., LHERMITTE, B., HEGI, M. E., ROSELL, J. & HENRIKSSON, R. 2012. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol, 13, 916-26.
MALMSTRöM, A., POULSEN, H. S., GRøNBERG, B. H., STRAGLIOTTO, G., HANSEN, S., ASKLUND, T., HOLMLUND, B., ŁYSIAK, M., DOWSETT, J., KRISTENSEN, B. W., SöDERKVIST, P., ROSELL, J. & HENRIKSSON, R. 2017. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. Acta Oncol, 56, 1776-1785.
MANSOURI, A., HACHEM, L. D., MANSOURI, S., NASSIRI, F., LAPERRIERE, N. J., XIA, D., LINDEMAN, N. I., WEN, P. Y., CHAKRAVARTI, A., MEHTA, M. P., HEGI, M. E., STUPP, R., ALDAPE, K. D. & ZADEH, G. 2019. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol, 21, 167-178.
NABORS, L. B., PORTNOW, J., AMMIRATI, M., BAEHRING, J., BREM, H., BUTOWSKI, N., FENSTERMAKER, R. A., FORSYTH, P., HATTANGADI-GLUTH, J., HOLDHOFF, M., HOWARD, S., JUNCK, L., KALEY, T., KUMTHEKAR, P., LOEFFLER, J. S., MOOTS, P. L., MRUGALA, M. M., NAGPAL, S., PANDEY, M., PARNEY, I., PETERS, K., PUDUVALLI, V. K., RAGSDALE, J., ROCKHILL, J., ROGERS, L., RUSTHOVEN, C., SHONKA, N., SHRIEVE, D. C., SILLS, A. K., SWINNEN, L. J., TSIEN, C., WEISS, S., WEN, P. Y., WILLMARTH, N., BERGMAN, M. A. & ENGH, A. 2017. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw, 15, 1331-1345.
OHGAKI, H. & KLEIHUES, P. 2005. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol, 64, 479-89.
OSTROM, Q. T., GITTLEMAN, H., TRUITT, G., BOSCIA, A., KRUCHKO, C. & BARNHOLTZ-SLOAN, J. S. 2018. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol, 20, iv1-iv86.
PERRY, J. R., LAPERRIERE, N., O'CALLAGHAN, C. J., BRANDES, A. A., MENTEN, J., PHILLIPS, C., FAY, M., NISHIKAWA, R., CAIRNCROSS, J. G., ROA, W., OSOBA, D., ROSSITER, J. P., SAHGAL, A., HIRTE, H., LAIGLE-DONADEY, F., FRANCESCHI, E., CHINOT, O., GOLFINOPOULOS, V., FARISELLI, L., WICK, A., FEUVRET, L., BACK, M., TILLS, M., WINCH, C., BAUMERT, B. G., WICK, W., DING, K. & MASON, W. P. 2017. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med, 376, 1027-1037.
STUPP, R., HEGI, M. E., GILBERT, M. R. & CHAKRAVARTI, A. 2007. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol, 25, 4127-36.
STUPP, R., HEGI, M. E., MASON, W. P., VAN DEN BENT, M. J., TAPHOORN, M. J., JANZER, R. C., LUDWIN, S. K., ALLGEIER, A., FISHER, B., BELANGER, K., HAU, P., BRANDES, A. A., GIJTENBEEK, J., MAROSI, C., VECHT, C. J., MOKHTARI, K., WESSELING, P., VILLA, S., EISENHAUER, E., GORLIA, T., WELLER, M., LACOMBE, D., CAIRNCROSS, J. G. & MIRIMANOFF, R. O. 2009. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 10, 459-66.
TESILEANU, C. M. S., SANSON, M., WICK, W., BRANDES, A. A., CLEMENT, P. M., ERRIDGE, S. C., VOGELBAUM, M. A., NOWAK, A. K., BAURAIN, J. F., MASON, W. P., WHEELER, H., CHINOT, O. L., GILL, S., GRIFFIN, M., ROGERS, L., TAAL, W., RUDà, R., WELLER, M., MCBAIN, C., VAN LINDE, M. E., ALDAPE, K., JENKINS, R. B., KROS, J. M., WESSELING, P., VON DEIMLING, A., HOOGSTRATE, Y., DE HEER, I., ATMODIMEDJO, P. N., DUBBINK, H. J., BROUWER, R. W. W., VAN, I. W. F. J., CHEUNG, K. J., GOLFINOPOULOS, V., BAUMERT, B. G., GORLIA, T., FRENCH, P. J. & VAN DEN BENT, M. J. 2022. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clin Cancer Res, 28, 2527-2535.
WICK, W., PLATTEN, M., MEISNER, C., FELSBERG, J., TABATABAI, G., SIMON, M., NIKKHAH, G., PAPSDORF, K., STEINBACH, J. P., SABEL, M., COMBS, S. E., VESPER, J., BRAUN, C., MEIXENSBERGER, J., KETTER, R., MAYER-STEINACKER, R., REIFENBERGER, G. & WELLER, M. 2012. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol, 13, 707-15.
XU, S., TANG, L., LI, X., FAN, F. & LIU, Z. 2020. Immunotherapy for glioma: Current management and future application. Cancer Lett, 476, 1-12.
ZHANG, J., STEVENS, M. F. & BRADSHAW, T. D. 2012a. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol, 5, 102-14.
ZHANG, N., ZHANG, L., QIU, B., MENG, L., WANG, X. & HOU, B. L. 2012b. Correlation of volume transfer coefficient Ktrans with histopathologic grades of gliomas. J Magn Reson Imaging, 36, 355-63.